What are the postremission treatment recommendations for high-risk patients with acute myeloid leukemia (AML)?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Cytogenetics [complex (≥3 clonal chromosomal abnormalities), -5, 5q-, -7, 7q-, 11q23 - non t(9;11), inv(3), t(3;3), t(6;9), t(9;22)] and molecular abnormalities (normal cytogenetics: FLT3-ITD mutation), prior antecedent hematologic disorder (AHD):

  • Allogeneic stem cell transplantation or

  • Clinical trial or

  • High-dose cytarabine 3 g/m2 IV over 3h every 12h on days 1, 3, and 5; if clinical trial not available or

  • High-dose cytarabine (3 g/m2 every 12 h on days 1, 3, and 5) plus  midostaurin 50 mg PO BID on days 8-21 of each 28-day cycle for up to four consolidation cycles, followed by  continuous midostaurin [9]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!